A Novel Marker for Screening Paroxysmal Nocturnal Hemoglobinuria Using Routine Complete Blood Count and Cell Population Data

Jimin Kahng, M.D., Yonggoo Kim, M.D., Jung Ok Kim, M.T., Kwangsang Koh, M.T., Jong Wook Lee, M.D., and Kyungja Han, M.D.

Departments of Laboratory Medicine and Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background: Final diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) may take years demanding a quick diagnosis measure. We used the facts that PNH cells are damaged in acid, and reagents for measuring reticulocytes in Coulter DxH800 (Beckman Coulter, USA) are weakly acidic and hypotonic, to create a new PNH screening marker.

Methods: We analyzed 979 complete blood counts (CBC) data from 963 patients including 57 data from 44 PNH patients. Standard criteria for PNH assay for population selection were followed: flow cytometry for CD55 and CD59 on red blood cells (RBCs) to a detection level of 1%; and fluorescent aerolysin, CD24 and CD15 in granulocytes to 0.1%. Twenty-four PNH minor clone-positive samples (minor-PNH+) were taken, in which the clone population was <5% of RBCs and/or granulocytes. Excluding PNH and minor-PNH+ patients, the population was divided into anemia, malignancy, infection, and normal groups. Parameters exhibiting a distinct demarcation between PNH and non-PNH groups were identified, and each parameter cutoff value was sought that includes the maximum [minimum] number of PNH [non-PNH] patients.

Results: Cutoff values for 5 selected CBC parameters (MRV, RDWR, MSCV, MN-AL2-NRET, and IRF) were determined. Positive rates were: PNH (86.0%), minor-PNH+ (33.3%), others (5.0%), anemia (13.4%), malignancy (5.3%), infection (3.7%), normal (0.0%); within anemia group, aplastic anemia (40.0%), immune hemolytic anemia (11.1%), iron deficiency anemia (1.6%). Sensitivity (86.0%), specificity (95.0%), PPV (52.1%), and NPV (99.1%) were achieved in PNH screening.

Conclusion: A new PNH screening marker is proposed with 95% specificity and 86% sensitivity. The flag identifies PNH patients, reducing time to final diagnosis by flow cytometry.

Key Words: Paroxysmal nocturnal hemoglobinuria, Screening marker, Complete blood count, Reticulocyte-related parameters

INTRODUCTION

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hemolytic disease, affecting only 1-2 persons per million worldwide; in Korea, there are about 300 reported patients [1]. PNH is caused by the absence of glycosylphosphatidylinositol (GPI)-linked proteins, due to phosphatidylinositol glycan A (PIG-A) gene mutation, rendering cells vulnerable to complement attack [2-4], especially in acidic blood ensued by sleep with shallow respiration [5]. Unlike mutations in normal, healthy individuals, the PIG-A mutation in PNH occurs in an affected multipotent hematopoietic stem cells [6]. With expansion of this mutant
clone, PNH is characterized by chronic complement-mediated hemolytic anemia, hemoglobinuria, thrombosis in unusual locations, acquired bone marrow failure, and relatively low risk of myelodysplastic syndrome or leukemia [7, 8].

Traditionally, the Ham test, using acidified serum as proposed in 1937 [9], and the sucrose hemolysis test, incubating blood in hypotonic sucrose solution [10], were used to diagnose PNH, although the sensitivities and specificities of examinations by spectrophotometry are quite low. Over the past several years, evaluation by flow cytometry of GPI-anchored proteins (CD55, CD59) of red blood cells (RBC) and granulocytes has become the gold standard for PNH diagnosis [11-13]; however, this approach has not been adopted by all laboratories, and hematology specialists are required for opportune diagnosis, which otherwise could be difficult to be established for a prolonged period of up to months or years.

Hence, it is of critical importance to introduce an expedient and facilitated measure for PNH diagnosis. This need is further enforced by the following considerations: the median survival of PNH patients is approximately 10 yr, the 5-yr mortality rate is about 35%, and the treatment with the Food and Drug Administration (FDA)-approved ecuulizumab (Soliris; Alexion Pharmaceuticals, Inc., Cheshire, CT, USA) for PNH is expected to considerably improve the five-year survival rate for patients, in addition to alleviating symptoms [11, 14-17].

We aimed to develop a measure by which PNH could be screened using data gathered from routine complete blood count (CBC) tests. Our study was driven by two observations: 1) PNH cells are more damaged than normal cells in acidic conditions, in which complements are activated, and 2) since the reagents used for measuring reticulocytes in a Coulter DxH800 (Beckman Coulter, Miami, FL, USA) are acidic and hypotonic, PNH cells should show different assay data than normal cells. On the basis of the routine parameters and research use only (RUO) parameters from the DxH800, the authors aimed to create a new screening marker for PNH composed of the fewest parameters, but offering the most discriminative power.

**METHODS**

1. **Study population**

We analyzed 979 CBC data from 963 patients. The CBC data include data from both PNH patients (57 samples from 44 PNH patients) and those receiving CBC exams for anemia, malignancy, infection, or health check-ups at Seoul St. Mary’s Hospital, Korea, between December 2012 and July 2014. In the selected population, we followed the standard criteria for the PNH assay. Flow cytometry for CD55 and CD59 on RBCs was performed to quantitate type I (normal expression), type II (partial deficiency), and type III (complete deficiency) PNH clones to a detection level of 1%. PNH clones in granulocytes were detected using fluorescent aerolysin [12] for CD24 and CD15 to a detection level of 0.1%. In addition to the PNH patients, aplastic anemia and myelodysplastic syndrome were also confirmed by flow cytometry to rule out PNH clones.

When the PNH-positive clone population was less than 5% of RBC and/or granulocyte counts (Fig. 1), the change of cell population data was expected to be less than 5%. Hence, it was considered that if these samples were treated as the overt cases with more than 5% of PNH clones, noise in the data might occur in establishing the screening marker. To avoid such noise, we classified and analyzed such samples as “PNH minor clone-positive samples” (minor-PNH+). There were 24 minor-PNH+ in the present study population. To ensure minimal sample bias, any two data from the same patient had a minimum test interval of one year between them. Excluding the PNH and minor-PNH+ patients, the remaining study population (control group) was composed of four subgroups: anemia, malignancy, infection,

**Fig. 1.** Examples of flow cytometric analysis for red blood cells in a paroxysmal nocturnal hemoglobinuria (PNH) patient with a clone size of 93.7% (A) and another PNH patient with a clone size of 4.9% (B).
and normal. The specific diseases and the patients’ characteristics for each group are shown in Table 1. This study was approved by The Catholic Medical Center institutional review board.

2. Establishment and analysis of the new markers

1) Selecting the parameters
Considering the characteristics of PNH, we examined 43 parameters in total: five basic CBC parameters such as hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, RBC distribution width; four reticulocyte-related parameters such as reticulocyte number and percent, mean reticulocyte volume (MRV), immature reticulocyte fraction (IRF); and 34 RUO parameters such as low hemoglobin density, microcytic anemia factor, mean sphered cell volume (MSCV), high light scattering reticulocyte, RBC size factor, reticulocyte distribution width (RDWR), and 28 volume/conductivity/light scatter (VCS) parameters [MN-V-RET, SD-V-RET, MN-C-RET, SD-C-RET, MN-AL2-RET, SD-AL2-RET, MN-MALS-RET, SD-MALS-RET, MN-UMALS-RET, SD-UMALS-RET, MN-LMALS-RET, SD-LMALS-RET, MN-LALS-RET, SD-LALS-RET, MN-V-NRET, SD-V-NRET, MN-C-NRET, SD-C-NRET, MN-AL2-NRET, SD-AL2-NRET, MN-MALS-NRET, SD-MALS-NRET, MN-UMALS-NRET, SD-UMALS-NRET, MN-LMALS-NRET, SD-LMALS-NRET, MN-LALS-NRET, and SD-LALS-NRET]. Each parametric data measured was sorted in increasing order of values. We manually tried to identify parameters that exhibited a comparatively distinct demarcation between PNH and non-PNH groups.

2) Establishing cutoff values
The whole samples were divided into two sets: test and validation, to find optimal cutoff values to rule out any interference originating from device conditions, especially from the laser [18]. All sample data were first organized by disease, and each disease group was subsequently sorted in chronological order. Each chronologically-ordered disease group was then divided into two sets: a test set and a validation set. The former included those samples that were placed in odd number positions in the ordered group, whereas the latter included the samples in even number positions. For each identified parameter, a cutoff value was sought that would include the maximum number of PNH patients and the minimum number of control samples. Establishing cutoff values involved manual sorting of parameter values in Excel in either decreasing or increasing order. A value was considered as a cutoff, if it would mark the most number of PNH samples and the least number of control samples. With the collected cutoff values, we fine-tuned the values to achieve a minimum of 90% sensitivity and specificity. Flow cytometry results were considered as truth values. The marker range set, obtained as described above, was subsequently applied to the validation set to verify its validity.

3. Statistical analysis
We used Student’s t-test or ANOVA to test differences in the means of hematologic parameters between groups and Spearman’s coefficient of rank sum test to find any correlation between PNH cell counts and each parameter. All statistical analyses including specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). The confidence interval (CI) was set to 95%, and P value less than 0.05 was considered statistically significant.

RESULTS

Table 2 shows the mean value of each of five parameters, which exhibits a distinct demarcation between PNH patients and non-

---

Table 1. Characteristics and diseases of the study population

|                | N    | M  | F  | Age (yr) |
|----------------|------|----|----|----------|
| PNH            | 57   | 30 | 27 | 42.3 ± 15.2 |
| Minor-PNH+     | 24   | 14 | 10 | 46.1 ± 17.1 |
| Control        | 898  | 494| 404| 43.2 ± 19.4 |
| Anemia         | 217  | 107| 110| 47.1 ± 20.5 |
| Aplastic anemia| 35   | 21 | 14 |          |
| Immune hemolytic anemia | 108  | 58 | 50 |          |
| Iron deficiency anemia | 63   | 21 | 42 |          |
| Others*        | 11   | 7  | 4  |          |
| Malignancy     | 131  | 72 | 59 | 43.8 ± 20.7 |
| Acute leukemia | 92   | 46 | 46 |          |
| Myelodysplastic syndrome | 23   | 13 | 10 |          |
| Chronic myelogenous leukemia | 11   | 9  | 2  |          |
| Others†        | 5    | 4  | 1  |          |
| Infection      | 241  | 129| 112| 54.4 ± 21.2 |
| Tuberculosis   | 53   | 31 | 22 |          |
| Sepsis         | 143  | 80 | 63 |          |
| Viral infection| 45   | 18 | 27 |          |
| Normal         | 309  | 186| 123| 31.6 ± 4.5 |

*Hereditary spherocytosis and sickle cell anemia; †Osteosarcoma, Ewing’s sarcoma, and neuroblastoma.
Abbreviations: PNH, paroxysmal nocturnal hemoglobinuria; M, male; F, female.

http://dx.doi.org/10.3343/alm.2015.35.1.35 www.anlabmed.org 37
PNH patients. A significant difference was found for each of the five parameters between the PNH and control groups ($P<0.001$). Except for the normal group within the control subgroups, the anemia, malignancy, and infection subgroups all showed a significant difference in the five parameters ($P<0.001$). In the normal subgroup, only RDWR showed an insignificant difference with the PNH group ($P=0.405$).

When these parameters are applied as a set, the cutoff values that ensured at least 90% specificity and 85% sensitivity are shown below:

1. MRV $>125$
2. RDWR $<30$
3. MSCV $>88$
4. MN-AL2-NRET $\geq 85$
5. IRF $\geq 0.4$

Followings are brief explanations for each of the selected parameters: MRV (fL) is the mean volume of all reticulocyte-events; RDWR is the size distribution of reticulocytes expressed as coefficient variation of width; MSCV (fL) is mean sphered cell volume of RBCs derived as a side effect from preparation for reticulocyte measurement; MN-AL2-NRET is mean of RBC volume measured by axial light loss in the reticulocyte channel; and IRF is a percentage of the count of the highest light scatter reticulocytes relative to the total reticulocyte count.

The performance of the new marker in the test set and in the validation set was satisfactory in screening PNH (Table 3).

Table 4 shows the positive rates for PNH, control, and minor-PNH+ groups, when the PNH marker, consisting of these five parameters, was applied. Briefly, the PNH group exhibited 86.0% positive rate, the control 5.0%, and minor-PNH+ 33.3%. The anemia subgroup had the highest positive rate (13.4%) of the control groups; within the anemia subgroup, aplastic anemia was the highest (40.0%) compared to immune hemolytic anemia (11.1%) and IDA (1.6%).

When compared between only the PNH group and control group, the PNH marker showed 86.0% sensitivity (95% CI; 73.7-93.3), 95.0% specificity (95% CI; 93.3-96.3), 52.1% PPV (95% CI; 41.6-62.4), and 99.1% NPV (95% CI; 98.1-99.6).

Each parameter generally showed poor correlation to the number of PNH cells found by flow cytometry. Type II erythrocytes were not found in the study samples. Type III erythrocyte count

---

**Table 2. Selected parameters in each group (mean ± SD)**

|        | MRV (fL) | RDWR (%) | MSCV (fL) | MN-AL2-NRET | IRF (%) |
|--------|----------|----------|-----------|-------------|---------|
| PNH    | $139.5 \pm 13.3$ | $25.8 \pm 1.4$ | $104.2 \pm 10.0$ | $100.6 \pm 10.1$ | $53.9 \pm 7.4$ |
| Minor-PNH+ | $137.6 \pm 11.5$ | $26.9 \pm 1.9$ | $91.9 \pm 9.8$ | $96.1 \pm 10.5$ | $50.0 \pm 8.3$ |
| Control | $114.9 \pm 14.9$ | $28.1 \pm 4.6$ | $89.5 \pm 8.0$ | $87.8 \pm 7.7$ | $41.6 \pm 12.5$ |
| Anemia | $120.4 \pm 18.8$ | $28.1 \pm 3.9$ | $88.1 \pm 11.4$ | $85.6 \pm 8.7$ | $46.2 \pm 14.2$ |
| Malignancy | $122.3 \pm 18.4$ | $31.7 \pm 5.5$ | $87.9 \pm 8.3$ | $88.2 \pm 8.9$ | $46.1 \pm 15.5$ |
| Infection | $111.2 \pm 14.3$ | $29.2 \pm 5.3$ | $90.8 \pm 7.3$ | $85.3 \pm 8.6$ | $40.4 \pm 13.3$ |
| Normal | $110.9 \pm 4.6$ | $25.6 \pm 1.9$ | $90.2 \pm 4.3$ | $91.2 \pm 2.7$ | $37.3 \pm 5.9$ |

$P$ values were provided when compared with PNH group.

**Table 3. Performance of the new marker in screening paroxysmal nocturnal hemoglobinuria**

|                  | N    | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | PPV (%) (95% CI) | NPV (%) (95% CI) | Correctly identified samples (%) |
|------------------|------|--------------------------|--------------------------|-----------------|-----------------|-------------------------------|
| Test set         | 478  | 93.1 (75.8-98.8)         | 95.1 (92.6-96.8)         | 55.1 (40.3-69.1) | 99.5 (98.1-99.9) | 95.0                          |
| Validation set   | 477  | 78.6 (58.5-91.0)         | 94.9 (92.3-96.7)         | 48.9 (33.9-64.0) | 98.6 (96.8-99.4) | 94.5                          |
| Study population | 955  | 86.0 (74.0-93.3)         | 95.0 (93.3-96.3)         | 52.1 (41.6-62.4) | 99.1 (98.1-99.6) | 94.5                          |

$P$ values were provided when compared with PNH group.

Abbreviations: PNH, paroxysmal nocturnal hemoglobinuria; MRV, mean reticulocyte volume; RDWR, reticulocyte distribution width; MSCV, mean sphered cell volume; MN-AL2-NRET, measuring mature RBC volume in the reticulocyte channel by light scattering; IRF, immature reticulocyte fraction.
was 37.9±36.6 (mean±SD), Type II granulocyte 0.4±1.2, and Type III granulocyte 52.6±43.2. Among the combinations of each parameter and PNH cell counts, only MN-AL2-NRET and type II granulocyte count showed a moderate correlation (r = 0.548, P <0.0001).

**DISCUSSION**

Using the same impedance methods as other CBC analyzers, DxH800 measures such primary CBC data as white blood cell, RBC, platelet count, MCV, RDW, and platelet distribution width; in addition, it uses VCS technology to determine white blood cell differential count and cell population data. VCS technology offers volumetric sizing of cells using direct current; conductivity according to the nuclear characteristics and granularity using alternating current in the radiofrequency range; and five light scatter signals (S; AL2, MALS, UMALS, LMALS, LALS) using a laser, providing comprehensive information regarding cell size, cell surface characteristics, and complexity of nucleus and cytoplasmic granules.

Also, in the reticulocyte channel of the Coulter DxH800, RBCs are processed in acidic hypoosmotic, ghosting solution to measure both reticulocyte-related parameters and RUO parameters [19, 20]. When reagent A (Retic A) containing new methylene blue and sulfuric acid is inserted into RBC, hemoglobin exudes out from the RBC, thus causing it to become a ghost cell. After fresh methylene blue staining, slight hypotonic and acidic reagent (Retic Clear, reagent B, pH 1.9) is added to clear the hemoglobin, and the parameters are promptly measured when RBCs are swollen in reagent B. In principle, this assay procedure resembles the Ham test and sugar water test, in that it is deemed PNH-positive when hemolysis is detected in RBCs in acidified serum or hypoosmotic conditions. The observation in which MRV, MSCV, MN-AL2-NRET, and IRF prominently increased in the PNH group in comparison with the control group is due to the characteristic of the PNH cell wherein it gets damaged easily in the reticulocyte channel and swells. On the other hand, there was no difference found with the normal subgroup for RDWR, which implies relative evenness of such characteristic changes in the PNH group. However, it is unknown why there is a higher value of RDWR for the anemia, malignancy, and infection subgroups of the control group than that for the PNH group.

With the established PNH marker, the minor-PNH+ group showed the expected positive rate belonging to the gray zone between the control group and PNH group. Minor-PNH+ does not present with PNH symptoms; however, it occurs either at the inception of mutation or with PNH following eculizumab treatment. Classical flow cytometric analysis for RBC CD55 and CD59 is not optimal in that PNH clone size can be affected by hemolysis or transfusion [21]. The same reason may have been true for our method as well; nevertheless, as a screening test, it is of high quality. To serve as a good quality screening test, satisfactory sensitivity is needed because patients with small PNH clones, such as AA/PNH, MDS/PNH, or subclinical PNH clones, are asymptomatic, while less than 10% of PNH clones rarely require clinical intervention, thus only the expansion of clones can be closely monitored [11].

The sensitivity of the validation set is lower than that of the test set, and if there had been more PNH samples, the sensitivity difference could be expected to be marginal. In attempting to increase sensitivity, the false positive rate increases; this is not a recommendable approach with diseases such as PNH with a very low prevalence. The present results demonstrate a high specificity, with an appropriate level of sensitivity and a high NPV, which helps exclude PNH in negative cases, and in positive cases provides a supplementary clinical means to test cases for potential PNH. It is very important that the new marker identified no patient from the normal group with suspected PNH. This ensures that there is a very low risk of performing flow cytometry for PNH-negative patients when our proposed PNH marker is used.

It was quite intriguing to see that the anemia group, especially aplastic anemia, showed a high positive rate, displaying the PNH disease spectrum. It is known that there is a high incidence of PNH minor clones in aplastic anemia patients. In light of our study, it is considered that aplastic anemia bears a significant resemblance to PNH before any incidence of PNH clones. Studies, including a prospective multicenter study, commonly show linkage between PNH and aplastic anemia and immune-mediated bone marrow failure [11, 12, 21-26]. These positive cases should be closely followed up, monitoring PNH clone expansion. Relatively quicker and highly probable responses to immunosuppressive therapy can be expected for AA/PNH patients than for aplastic anemia patients with GPI-AP-deficient erythrocytes [27].

In the anemia group, immune hemolytic anemia falls just below aplastic anemia in the order of high false positive rates (11.1%), suggesting common hemolytic cell changes affecting the marker range. A hemolytic period, as a part of the PNH disease process, especially requires distinction from immune hemolytic anemia; therefore, patients with hemolytic anemia should first be screened using the proposed marker and confirmed by
flow cytometry for a final diagnosis.

Because of the many co-occurrences of IDA, it is significant that, when comparing separately with IDA group, specificity increased to 98.4%. Thus, the criteria set forth in this study enable differential diagnosis of simple IDA with PNH.

In conclusion, a mere CBC exam can screen PNH with 95% specificity and 86% sensitivity. Furthermore, using five CBC parameters as PNH markers facilitates identification of PNH patients, thus considerably reducing the time required to a final diagnosis by flow cytometry. The limitation of the proposed PNH screening marker in this study lies in that the marker can be applied only to the Coulter DxH800.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol 2013;97:749-57.
2. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11.
3. Rosse WF and Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277-86.
4. Rollins SA and Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990;144:3478-83.
5. Parker CJ. Paroxysmal nocturnal hemoglobinuria: an historical overview. Hematology Am SocHematolEdu Program 2008;93-103.
6. Brodsky RA and Hu R. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leuk Lymphoma 2006;47:1215-21.
7. Sugimori C, Machizuki K, Qi Z, Sugimori N, Ishiyama K, Kondo Y, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009;147:102-12.
8. Raza A, Ravandi F, Rastagi A, Bubis J, Lim SH, Weitz I, et al. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytotherapy B ClinCytom 2014;86:175-82.
9. Ham TH and Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: Certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Invest 1939;18:657-72.
10. Hartmann RC and Jenkins DE. The “sugar-water” test for paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966;275:155-7.
11. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113:6522-7.
12. Borowitz MJ, Craig FE, Digijuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytotherapy B ClinCytom 2010;78:211-30.
13. Höchsmann B, Rojewski M, Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann Hematol 2011;90:887-99.
14. Muñoz-Linares C, Ojeda E, Forés R, Pastrana M, Cabero M, Morillo D, et al. Paroxysmal nocturnal hemoglobinuria: a single Spanish center’s experience over the last 40 yr. Eur J Haematol 2014;93:309-19.
15. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43.
16. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7.
17. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-92.
18. Park J, Lee H, Kim YK, Kim KH, Lee W, Lee KY, et al. Automated screening for tuberculosis by multiparametric analysis of data obtained during routine complete blood count. Int J Lab Hematol 2014;36:156-64.
19. Urrechaga E. Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erythropoiesis. Int J Lab Hematol 2009;31:623-9.
20. Broséus J, Visomblain B, Guy J, Mynadidé M, Girodon F. Evaluation of mean spherical corpuscular volume for predicting hereditary spherocytosis. Int J Lab Hematol 2010;32:519-23.
21. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.
22. Griscelli-Bennaceur A, Gluckman E, Scrobobaci ML, Jonveaux P, Yu T, Bazarbachi A, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood 1995;85:1354-63.
23. Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal hemoglobinuria-type cells, and an aplastic anemia-associated autoantibody in children with acquired aplastic anemia. Br J Haematol 2008;142:427-35.
24. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anemia. Br J Haematol 2009;144:206-16.
25. Timeus F, Crescentino N, Lorenzati A, Doria A, Mavilaux P, Yu T, Bazarbachi A, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria clone presence in aplastic anemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol 2010;150:483-5.
26. Kulagin A, Lisukov I, Ivanova M, Golubovskaya I, Kruchkova I, Bondarenko S, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol 2014;164:546-54.
27. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-14.